Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome Holdings (HIND) reported a third-quarter 2026 loss per share of $0.13, narrowing year over year as VT-1953 development continued. The prior-year loss was $3.06 per share; that comparison reflects merger-related charges and changes in weighted-average shares. Quarterly revenue rose to $57,998 from $34,627, while nine-month revenue fell to $116,544 from $283,163. Quarterly net loss narrowed to $930,325 from $8,595,300.
Cash reached $6,956,822 at September 30, 2026, versus $4,982,333 at year-end 2025. Vyome continued VT-1953 product development and manufacturing preparations and plans further FDA discussion through a Type C meeting before advancing its proposed clinical program. It is preparing a response to the FDA’s request for additional information on orphan drug designation. VT-1908 formulation work continued, and related U.S. patent claims received a Notice of Allowance in October.
Vyome Holdings (HIND) congratulated Scientific Co-Founder and Director Dr. Shiladitya Sengupta on his promotion to Professor of Medicine at Harvard Medical School. His research spans disease mechanisms and therapeutic technologies, particularly in oncology, inflammation and drug delivery.
Dr. Sengupta remains a Vyome Co-Founder and Director. His academic achievement is independent of Vyome’s clinical and regulatory programs. The company’s programs include investigational topical therapies VT-1953 for symptoms associated with malignant fungating wounds and VT-1908 as a potential non-steroidal treatment for anterior uveitis.
Vyome Holdings (Nasdaq: HIND) received a USPTO Notice of Allowance covering formulations and methods of use underlying its VT-1908 ocular inflammation program. The allowed claims relate to U.S. Patent Application No. 17/787,303. VT-1908 is a topical eye formulation of mycophenolate, a drug that modifies immune activity, being developed initially for anterior uveitis, an inflammatory eye condition.
Preclinical results published in February 2026 in the Journal of Ophthalmic Inflammation and Infection showed therapeutic drug concentrations in the eye, reduced inflammation in a uveitis model, and efficacy comparable to topical steroids. Vyome envisions development for a broader range of ocular and periocular inflammatory conditions beyond its initial uveitis focus.
Vyome Holdings (HIND) appointed veteran finance executive Jerry Leonard, CPA, MBA, as Chief Financial Officer effective September 1, 2026.
Leonard will oversee Vyome’s financial operations, reporting, accounting, internal controls and related corporate governance. He succeeds Robert Dickey IV, who had served as Interim CFO since August 2025. The company highlights Leonard’s more than 25 years of experience in financial management, business leadership and corporate strategy.
Leonard is founder and CEO of ClearBridgeCFO and previously served as SVP, CFO and Secretary of VSee Health after its 2024 business combination, and as CFO of iDoc Virtual Telehealth Solutions and VSee Lab. Earlier roles included finance leadership positions at Voya Financial, IBM and Colgate-Palmolive, following an early career in public accounting at Arthur Andersen and PwC.
Vyome Holdings (Nasdaq: HIND) reported second quarter 2026 results and clinical progress for lead candidate VT-1953 for malignant fungating wounds. Phase 2 data showed statistically significant improvements in malodor, patient-reported impact on daily life, and lesion pain, with no treatment-emergent adverse events.
In March 2026, Vyome submitted a pre-IND briefing package to the FDA outlining a proposed pivotal study strategy and received written feedback in the second quarter. The company is preparing additional materials and plans a Type C meeting to further advance VT-1953. Vyome also in-licensed two selective JAK inhibitor assets from Impetis Biosciences and obtained a granted Chinese patent for VB-1953 in inflammatory acne.
As of June 30, 2026, cash and cash equivalents were approximately $7.9 million versus $5.0 million at year-end 2025. Second quarter 2026 operating expenses were about $874,000, and net loss attributable to common shareholders was approximately $720,000, or $0.10 per share.
Vyome (NASDAQ:HIND) received a new Chinese patent covering formulation and therapeutic use claims for its besifloxacin topical gel for inflammatory acne. The patent broadens protection to acne, associated inflammation, and antibiotic-resistant Propionibacterium acnes in China, an estimated $600 million prescription acne market, supporting future partnering and regional commercialization.
Vyome Holdings (Nasdaq:HIND) reported Q1 2026 results and regulatory progress. The company ended the quarter with approximately $8.8 million in cash and no debt, preferred stock, or toxic financing instruments. Net loss was about $963,000, or $0.15 per share.
Vyome advanced VT-1953 toward pivotal readiness, submitted an FDA Orphan Drug Designation application, and presented positive Phase 2 data. It also in-licensed selective JAK inhibitor assets from Impetis Biosciences and raised roughly $5.29 million in equity, implying around 15% dilution.
Vyome (Nasdaq: HIND) presented Phase 2 data showing VT-1953 gel produced statistically significant reductions in malignant fungating wound (MFW) malodor and pain by Day 14 (primary endpoint: median TELER score improved from 0.5 to 4; P=0.0020).
Additional highlights: superiority versus vehicle (P=0.0015), 70% of VT-1953 patients reported improved malodor impact versus 0% for vehicle (P=0.0256), a 2-point median pain improvement (P=0.0020), and no treatment-emergent adverse effects reported.
Vyome (Nasdaq: HIND) will present complete Phase 2 clinical and supporting preclinical data for VT-1953 as a potential treatment for malodor and symptoms of malignant fungating wounds (MFW) at AACR 2026 on April 21, 2026.
Vyome said VT-1953 is first-in-class with a dual mechanism (DNA Gyr inhibition and MD2/TLR modulation). The company plans FDA interactions in Q2 2026 and is advancing VT-1953 toward pivotal studies; third-party analysts estimate a ~USD 2.2 billion U.S. TAM. MFW affects ~10% of advanced cancer patients.
Vyome (Nasdaq: HIND) completed a streamlined Nasdaq listing via merger, holds a clean capital structure with 5,919,337 common shares and no preferred stock or debt. Final Phase 2 data for VT-1953 showed statistically significant malodor reduction (P<0.002) and favorable safety.
Total cash was approximately $4.94M at 12/31/2025 plus an $5.3M ATM financing in Jan 2026, supporting runway to mid-2027; independent valuation placed VT-1953 at ~$1B post-Phase 3.